- PCB39: Eight hour drafting session charts future course for UNAIDS work program on Intellectual Property and the UN HLP
- PCB39: Statement of Knowledge Ecology International on Agenda item 6: UNAIDS synthesis report on IP
- UNAIDS PCB 39: Statement of India on the Executive Director's Report to the 39th PCB
- EB140: World Health Organization publishes annotated agenda for January 2017 Executive Board
- SCCR33: Conclusions - Protection of Broadcasting Organizations
- SCCR33: Conclusions - Artist Resale Right (droit de suite)
- SCCR33: Conclusions - Proposal for Analysis of Copyright Related to the Digital Environment
- SCCR 33, KEI's intervention on legal protection for technological protection measures
- SCCR33 - Statement by the Latin American and Caribbean Group (GRULAC) - Limitations on liability for libraries and archives
- SCCR 33: NGOs Statements on Casting treaty in Plenary November 16, 2016
27 June 2016
KEI statement on exceptions and limitations to patent rights
In relation to limitations and exceptions, we recall Brazil’s prescient submission, document SCP/14/7 (tabled in January 2010) which called attention to the lack of policy coherence in a world where in certain international fora, countries endorse the use of compulsory licensing to promote access to medicines for all, and in separate fora, criticize developing countries for actually considering or issuing such compulsory licenses.
In the wake of the NIH's letter to KEI declining to use the government's rights in the federally-funded patents on Xtandi under the Bayh Dole Act, it is interesting to consider that even the Gates Foundation, hardly the anti-patent group, maintains certain programs and policies to ensure that Gates-funded inventions are used for charitable purposes, with limitations on pricing.
Dr. S. Ward Casscells took the stage at the 2011 Innovative Minds in Prostate Cancer Today (IMPaCT) Meeting as a prostate cancer patient, a doctor, an Army Reserve colonel, and the former top doctor for the Pentagon. There, he praised the central role of the Department of Defense in bringing important prostate cancer medicines to market, including Xtandi (referred to by its experimental name, MDV3100), an expensive prostate cancer drug that was funded from basic research through phase I and II clinical trials by taxpayer and charitable funds.
National Institutes of Health Declines to Exercise Authority to Lower Xtandi Price
The National Institutes of Health will not use its rights under the Bayh-Dole Act to end the monopoly on the expensive prostate cancer drug Xtandi and allow low-priced generic versions to compete on the market.
Human Rights Council heats up during informal talks on the primacy of human rights over international trade and IP regimesSubmitted by thiru on 18. June 2016 - 5:02
At the 32nd session (13 June 2016 - 1 July 2016) of the Human Rights Council, a bloc of countries known as the the Core Group (Brazil, Egypt, Indonesia, India, Senegal, South Africa and Thailand) have tabled a resolution on access to medicines "premised on the primacy of human rights over international trade, investment and intellectual property regimes." The draft resolution complements the work of the United Nations High-Level Panel on Access to Medicines in reviewing and assessing “proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inven
Health Minister Alejandro Gaviria issued a declaration that it would be in the public interest for the government to lower the price of Novartis’ expensive leukemia drug, Gleevec (imatinib).
CONTACT: Andrew Goldman, +1 (202) 332-2670 or firstname.lastname@example.org
The following individuals are also available for comment:
- Andrea Carolina Reyes Rojas, Misión Salud: email@example.com
- Dr. Francisco Rossi, IFARMA: firstname.lastname@example.org
Washington, DC, June 17, 2016 — Colombian Minister of Health Alejandro Gaviria today issued Resolution 2475 of 2016, declaring that it would be in the public interest for the government of Colombia to lower the price of an expensive leukemia drug. The Ministry of Health describes this resolution as unprecedented in Colombia.
The drug, imatinib, is marketed as Glivec in Colombia by the Swiss pharmaceutical company Novartis at a price of approximately $15,000 per patient per year, nearly twice the average income of a Colombian resident. Glivec has generated over $47 billion in global revenue for Novartis.
More on this dispute at http://keionline.org/colombia
In response to the recent announcement from Colombia's Ministry of Health that a public interest declaration regarding imatinib will be issued in a matter of days, Novartis issued a statement that criticized the forthcoming action, saying, "We have consistently said that Declarations of Public Interest can be important and legitimate tools to be used only in exceptional circumstances," and saying "this is simply not the case in Colombia."
|David Hirschmann, US Chamber, claims efforts to curb high prices for cancer drugs are "a destructive course."
The US Chamber of Commerce might consider renaming itself the US/Swiss Chamber of Commerce, after their most recent attack on the Colombia Minister of Health (MoH) announcement that a "Declaration of Public Interest" would be issued for the patents on the cancer drug imatinib, held by the Swiss company Novartis. In the US Chamber's defense of the Swiss drug company, they don't mention the fact that Novartis has earned about $48 billion from sales of imatinib (sold by Novartis under the brand names Gleevec or Glivec) since the drug was put on the market, including more than $380 million per month in 2015.
Alfred Engelberg and Aaron Kesselheim in Nature on Bayh-Dole royalty free rights in patents, Xtandi caseSubmitted by James Love on 9. June 2016 - 10:33
Alfred Engelberg and Aaron Kesselheim have published an opinion article in Nature titled:
"Use the Bayh-Dole Act to lower drug prices for government healthcare programs," Nature Medicine 22, 576 (2016) doi:10.1038/nm0616-576, Published online 07 June 2016.
Colombia Ministry of Health Announces that Negotiations With Novartis Have Failed; Declaration of Public Interest ImminentSubmitted by Andrew Goldman on 8. June 2016 - 14:38
Reports have emerged from a DNDi meeting in Rio de Janeiro, Brazil, that the Colombian Ministry of Health announced that negotiations with Novartis over the price of Glivec have failed, and that Minister Alejandro Gaviria will proceed with the formal declaration that a compulsory license for the patents on the drug is in the public interest.
WIPO IGC30: Questions remain on protection of genetic resources as hard decisions postponed until 2017Submitted by Staff on 7. June 2016 - 1:00
By Sophia Simon
US proposal to seek a "better understanding" of Switzerland's implementation of the Nagoya Protocol receives chilly receptionSubmitted by thiru on 6. June 2016 - 2:21
*The author thanks Professor Marc Perlman (Brown University) for his comprehensive notes on the IGC deliberations of 3 June 2016.
By Sophia Simon
This week, the World Intellectual Property Organization (WIPO) is convening the 30th session of the Intergovernmental Committee (IGC) on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (GRTKF) from 30 May 2016 to 3 June 2016. The goal of this week’s session is to "[u]ndertake negotiations on [genetic resources] GRs with a focus on addressing unresolved issues" and to consider "options for a draft legal instrument." The Committee is chaired by Ian Goss (Australia).
WIPO IGC30: Clean and track-changed version of Facilitators' text on Intellectual Property and Genetic ResourcesSubmitted by thiru on 2. June 2016 - 4:04
In October 2015 the General Assembly of the World Intellectual Property Organization (WIPO) renewed the mandate of the the Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore (GRTKF):
The following is the intervention on behalf of Stichting Health Action International (HAI) at 69th World Health Assembly, Agenda Item 11.3 - Framework of engagement with non-State actors.
KEI worked with HAI on the statement, and the statement was delivered by Thiru Balasubramaniam